000181893 001__ 181893
000181893 005__ 20251118115221.0
000181893 0247_ $$2doi$$a10.1158/1078-0432.CCR-21-1258
000181893 0247_ $$2pmid$$apmid:36166660
000181893 0247_ $$2ISSN$$a1078-0432
000181893 0247_ $$2ISSN$$a1557-3265
000181893 0247_ $$2altmetric$$aaltmetric:136528049
000181893 037__ $$aDKFZ-2022-02290
000181893 041__ $$aEnglish
000181893 082__ $$a610
000181893 1001_ $$00000-0002-7260-532X$$aPinter, Matthias$$b0
000181893 245__ $$aNASH and hepatocellular carcinoma: immunology and immunotherapy.
000181893 260__ $$aPhiladelphia, Pa. [u.a.]$$bAACR$$c2023
000181893 3367_ $$2DRIVER$$aarticle
000181893 3367_ $$2DataCite$$aOutput Types/Journal article
000181893 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1763463123_1939190$$xReview Article
000181893 3367_ $$2BibTeX$$aARTICLE
000181893 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000181893 3367_ $$00$$2EndNote$$aJournal Article
000181893 500__ $$a#LA:F180# / 2023 Feb 1;29(3):513-520 / #DKFZ-MOST-Ca197#
000181893 520__ $$aThe last 10 years have revolutionized our basic understanding of non-alcoholic fatty liver disease and consequent liver cancer. It has become clear that several innate and adaptive immune cells play an important role in initiating, maintaining or exacerbating non-alcoholic steatohepatitis (NASH) - a disease that has been recently defined as auto-aggressive. Despite improved disease management aimed at reducing the progression of fibrosis, NASH is set to become a leading cause for hepatocellular carcinoma (HCC). Preliminary data from preclinical studies suggest that immunotherapy efficacy may be reduced in NASH-related HCC compared to viral HCC, however conclusive evidence supporting clinical translation of these findings is lacking. Comprehensive clinical and immunologic phenotyping of mechanisms linking NASH progression with carcinogenesis and therapeutic resistance is key to prevent progression to cirrhosis, improve monitoring and stratification of NASH according to predicted cancer risk and ultimately increase survival of NASH-HCC patients. In this review we summarize the state of the art in the field of NASH and NASH-HCC - with focus on immunobiology. We discuss pre-clinical and clinical findings underpinning NASH as an immunologically distinct pro-tumorigenic disease entity, and explore areas of potential therapeutic vulnerabilities in NASH-associated HCC.
000181893 536__ $$0G:(DE-HGF)POF4-316$$a316 - Infektionen, Entzündung und Krebs (POF4-316)$$cPOF4-316$$fPOF IV$$x0
000181893 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000181893 7001_ $$00000-0002-3529-0103$$aPinato, David J$$b1
000181893 7001_ $$0P:(DE-He78)6e985c345eb4618b127cf0fe1bff1522$$aRamadori, Pierluigi$$b2$$udkfz
000181893 7001_ $$0P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5$$aHeikenwälder, Mathias$$b3$$eLast author$$udkfz
000181893 773__ $$0PERI:(DE-600)2036787-9$$a10.1158/1078-0432.CCR-21-1258$$gp. CCR-21-1258$$n3$$p513-520$$tClinical cancer research$$v29$$x1078-0432$$y2023
000181893 909CO $$ooai:inrepo02.dkfz.de:181893$$pVDB
000181893 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6e985c345eb4618b127cf0fe1bff1522$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000181893 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)66ed2d4ec9bc11d29b87ac006adf85e5$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000181893 9131_ $$0G:(DE-HGF)POF4-316$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vInfektionen, Entzündung und Krebs$$x0
000181893 9141_ $$y2022
000181893 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-03
000181893 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-03
000181893 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-03
000181893 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000181893 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000181893 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-25
000181893 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000181893 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-25
000181893 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCLIN CANCER RES : 2022$$d2023-08-25
000181893 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000181893 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bCLIN CANCER RES : 2022$$d2023-08-25
000181893 9202_ $$0I:(DE-He78)F180-20160331$$kF180$$lChronische Entzündung und Krebs$$x0
000181893 9201_ $$0I:(DE-He78)F180-20160331$$kF180$$lChronische Entzündung und Krebs$$x0
000181893 980__ $$ajournal
000181893 980__ $$aVDB
000181893 980__ $$aI:(DE-He78)F180-20160331
000181893 980__ $$aUNRESTRICTED